11.3 Renal & Genitourinary Imaging

Renal & Genitourinary Imaging

Nuclear medicine offers unparalleled insights into renal function. While structural modalities like ultrasound, CT, and MRI provide exquisite anatomical detail of the kidneys, nuclear medicine renal scintigraphy quantifies the physiological performance of the renal system. It can measure overall and differential kidney function, evaluate the excretory pathway for obstruction, and detect subtle cortical scarring.

Renal Radiopharmaceuticals

Selecting the correct radiopharmaceutical is critical, as different agents trace entirely different physiological pathways within the kidney.

Tc-99m MAG3 (Mercaptoacetyltriglycine)

Tc-99m MAG3 is the most commonly used agent for dynamic renal imaging.

• Mechanism: It is cleared from the blood primarily by tubular secretion (approximately 90%), with a small amount filtered by the glomeruli.
• Function: Because of its high extraction efficiency by the proximal tubules, it is the agent of choice for evaluating effective renal plasma flow (ERPF) and calculating the Tubular Extraction Rate (TER).
• Clinical Advantage: MAG3 is highly protein-bound in the blood, which prevents it from diffusing into the interstitial spaces. Its high extraction fraction makes it the superior choice for patients with impaired renal function or pediatric patients.

Tc-99m DTPA (Diethylenetriaminepentaacetic acid)

Tc-99m DTPA is another dynamic imaging agent, but its mechanism is distinct from MAG3.

• Mechanism: It is cleared exclusively by glomerular filtration, with no tubular secretion and no reabsorption.
• Function: Because its clearance perfectly mirrors the filtration rate of the glomeruli, DTPA is the standard agent used to calculate the true Glomerular Filtration Rate (GFR).
• Clinical Advantage: While excellent for GFR calculation, DTPA's lower overall extraction efficiency compared to MAG3 makes it less ideal for evaluating the urinary tract in patients with poor renal function.

Tc-99m DMSA (Dimercaptosuccinic acid)

Unlike MAG3 and DTPA, which wash through the kidneys and into the bladder, Tc-99m DMSA is a static imaging agent.

• Mechanism: It binds tightly to the cells of the renal cortex (specifically the proximal convoluted tubules). It is cleared very slowly, with about 40% of the dose remaining fixed in the renal cortex at 6 hours post-injection.
• Function: DMSA provides high-resolution static images of the functioning cortical tissue.
• Clinical Advantage: It is the gold standard for detecting acute pyelonephritis (which appears as focal areas of decreased uptake) and chronic renal scarring (often a sequela of vesicoureteral reflux in children).

Diuresis Renography (Lasix Scan)

A common clinical dilemma is a patient presenting with a dilated renal pelvis (hydronephrosis) on ultrasound. This dilation could be due to a true mechanical obstruction (like a kidney stone or stricture), or it could simply be a non-obstructed, hypotonic "baggy" pelvis.

To differentiate these, a diuretic renogram is performed using MAG3 or DTPA, combined with the administration of Furosemide (Lasix), a potent loop diuretic.

The Procedure:

1. The radiotracer is injected, and a dynamic acquisition begins.
2. As the tracer fills the dilated renal pelvis, the activity curve on the renogram rises and plateaus (a prolonged retention phase).
3. Lasix is administered intravenously (standard adult dose is 40 mg, or a weight-based dose for pediatrics).
4. The response to the diuretic challenge is monitored.

Interpretation:

• Non-obstructed (Hypotonic Pelvis): The massive increase in urine flow induced by the Lasix rapidly washes the accumulated radiotracer out of the renal pelvis. The renogram curve demonstrates a rapid, steep decline.
• Mechanical Obstruction: Despite the massive increase in urine production, the physical blockage prevents the fluid from draining. The radiotracer remains trapped in the renal pelvis, and the renogram curve remains flat or continues to rise.

ACE Inhibitor Renography (Captopril Scan)

Renovascular hypertension is a specific, potentially curable form of high blood pressure caused by renal artery stenosis (RAS). When the renal artery is narrowed, blood flow to the kidney drops. The kidney misinterprets this as systemic hypotension and releases renin, activating the Renin-Angiotensin-Aldosterone System (RAAS).

Crucially, angiotensin II constricts the efferent arteriole (the exit vessel of the glomerulus). This constriction increases the back-pressure within the glomerulus, artificially maintaining the Glomerular Filtration Rate (GFR) despite the poor overall blood supply.

The Procedure: An ACE Inhibitor challenge scan unmasks this physiological compensation.

1. A baseline MAG3 or DTPA scan is performed. Often, the scan looks relatively normal because angiotensin II is propping up the GFR.
2. On a separate day (or in a one-day protocol), the patient is given an Angiotensin-Converting Enzyme (ACE) inhibitor, usually oral Captopril (25-50 mg) or intravenous Enalaprilat.
3. The ACE inhibitor blocks the production of angiotensin II.
4. The efferent arteriole relaxes, the compensatory back-pressure is lost, and the GFR of the affected kidney plummets.

Interpretation: A positive study for renovascular hypertension demonstrates a significant deterioration in renal function (delayed uptake and prolonged retention of MAG3, or severely decreased GFR with DTPA) in the affected kidney after the administration of Captopril, compared to the baseline study.